Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christopher J. Nixon"'
Autor:
Pan F. Chan, Kaushik Raha, Shruti Jain, Geoffrey Quinque, Margarete Neu, Daniele Andreotti, Roberto Profeta, Reema K. Thalji, Brian Donovan, Simona Tommasi, Lynn McCloskey, Christopher J. Nixon, Giovanni Meneghelli, Tania Bakshi, Anna Checchia, Robert A. Stavenger, Benjamin D. Bax, Alison Howells, Federica Tonelli, Haifeng Cui
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 29:1407-1412
A series of DNA gyrase inhibitors were designed based on the X-ray structure of a parent thiophene scaffold with the objective to improve biochemical and whole-cell antibacterial activity, while reducing cardiac ion channel activity. The binding mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f63ff5d1f9eeb44a22b39b1dba435047
https://doi.org/10.1016/j.bmcl.2019.03.029
https://doi.org/10.1016/j.bmcl.2019.03.029
Autor:
Christopher J. Nixon, Claire Y. Townsend, Stan F. Martens, Deepak Bandyopadhyay, Brian.T.Donovan Brian.T.Donovan, Chaya Duraiswami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60b061a1c10bcfac098ba8e22febe6bf
https://doi.org/10.1021/scimeetings.0c02370
https://doi.org/10.1021/scimeetings.0c02370
Autor:
Brian Donovan, Deepak Bandyopadhyay, Christopher J. Nixon, Stan F. Martens, Chaya Duraiswami, Claire Y. Townsend
Publikováno v:
European Journal of Pharmacology. 818:306-327
Despite the importance of the hERG channel in drug discovery and the sizable number of antagonist molecules discovered, only a few hERG agonists have been discovered. Here we report a novel hERG agonist; SKF-32802 and a structural analog of the agoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f404e55b60b59c8b797ffec8e1a510f
https://doi.org/10.1016/j.ejphar.2017.10.015
https://doi.org/10.1016/j.ejphar.2017.10.015
Autor:
Laste Stojanovski, Tania Bakshi, Iain H. Reid, Maria L. Marco, Stephen Brand, Lars Henrik Sandberg, Sabrinia D. Crouch, Ian H. Gilbert, Lorna MacLean, Jennifer Riley, Christopher J. Nixon, Sharon Robinson, John M. Kelly, Yoko Shishikura, Stephen Thompson, Eun Jung Ko, Kevin D. Read, Daniel Spinks, Jose M. Fiandor, John Thomas, Alan P. Hill, Amanda F. Francisco, Ola Epemolu, Victoria Smith, Chimed Jansen, Paul G. Wyatt, Elisabet Viayna, Sean J. Hindley, Timothy J. Miles, Shiromani Jayawardhana, Frederick R. C. Simeons, Michael G. Thomas, Manu De Rycker, Tim Underwood, Paul Scullion, Maria Osuna-Cabello
Publikováno v:
Journal of Medicinal Chemistry
Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8f828f15d0a52e1f719409da74fd5b
http://europepmc.org/articles/PMC5601362
http://europepmc.org/articles/PMC5601362
Autor:
Stephanie Chen, Mehul Patel, Louis V. LaFrance, Glenn S. Van Aller, BaoChau Le, Sharon Sweitzer, Yong Jiang, Andrew J. Pope, Danielle Key, Zining Wu, Christopher J. Nixon, Ryan G. Kruger, Melissa B. Pappalardi, Caretha L. Creasy, Carl A. Machutta, Michael T. McCabe, Sara H. Thrall, Benjamin Schwartz, Martin Brandt, Elsie Diaz, Sharad K. Verma, Glenn A. Hofmann, Peter J. Tummino
Publikováno v:
Journal of biomolecular screening. 17(10)
Histone methyltransferases (HMT) catalyze the methylation of histone tail lysines, resulting in changes in gene transcription. Misregulation of these enzymes has been associated with various forms of cancer, making this target class a potential new a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cf081021cb76a8796692374384fa80
https://pubmed.ncbi.nlm.nih.gov/22904200
https://pubmed.ncbi.nlm.nih.gov/22904200
Autor:
Stan F. Martens, Brian Donovan, Sarah E. Galbraith, Lisa A. Payne, Christopher J. Nixon, Tania Bakshi
Publikováno v:
Journal of pharmacological and toxicological methods. 64(3)
Introduction The development of drug candidates must take into account that many compounds have off-target activity against voltage-gated ion channels (VGIC) which may prevent their progression to market. Of particular concern are hERG and hNa V 1.5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d0d376993be8fcb027bf1da5730a63f
https://pubmed.ncbi.nlm.nih.gov/21996251
https://pubmed.ncbi.nlm.nih.gov/21996251